Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2015

View Archived Issues

Enumeral anti-PD-1 and anti-TIM-3 antibodies may potentiate antitumor immune responses

NIAID awards SRI International contract to develop treatments for radiation exposure

Progress made by the Center for Infectious Disease Research's partnership with GSK on TB

Johnson & Johnson Innovation announces new collaborations

Ultragenyx reports interim data from phase II study of UX-007

Sunshine Lake Pharma and Calitor Sciences present kinase inhibitors

Ignyta and Cancer Research Technology divulge PKC iota inhibitors

OPKO subsidiary and Vanderbilt University School of Medicine collaborate on genomics

Once-weekly growth hormone NN-8640 shows promise in phase I trial

Lilly and ImaginAb enter into preclinical research collaboration in immuno-oncology

Karolinska Institutet coordinates study of stem cells in unborn babies with osteogenesis imperfecta

MSD submits NDA for desloratadine in Japan

First-in-human results presented for personalized immunotherapy

Enzyme replacement therapy developed for MPS IIID

Roche patents autotaxin inhibitors

ViroCarb divulges HIV viral entry inhibitors

Transition Therapeutics reports data from phase II/III trial of ELND-005

Nordic Nanovector revises clinical development plan for Betalutin

New compound targets P2X purinoceptor 7 in experimental uveitis

EMA adopts positive opinion on new orphan designations for KTE-C19

Topical therapy Tendoncel shows promise in phase II study of tendon injury

Eisai and Ajinomoto sign agreement to form gastrointestinal specialty company

FDA issues complete response letter for saxagliptin/dapagliflozin NDA

Loxo Oncology initiates phase II basket trial of LOXO-101 for solid tumors with TRK fusions

MacroGenics provides update on several DART programs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...